Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma: a Single-arm Phase 2 Trial
Peking University First Hospital
37 participants
Oct 10, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy (ADT) in participants with androgen receptor (AR) positive, high-risk salivary duct carcinoma (SDC). The procedures include screening, treatment and follow-up period. The treatment includes rezvilutamide plus Luteinizing Hormone Releasing Hormone agonist (LHRHa) for up to 2 years.
Eligibility
Inclusion Criteria11
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Histologically confirmed salivary duct carcinoma and stage III or IVa or IVb according to AJCC Cancer Staging Manual Eighth Edition
- Completed SDC surgery, and adjuvant radiotherapy is planned or ongoing or has completed
- Androgen receptor (AR) positive
- White blood cell (WBC) ≥ 3.0 x 10\^9/L, Neutrophil count≥ 1.5 x 10\^9/L, Platelet count (PLT) ≥ 75 x 10\^9/L, Haemoglobin (Hb) ≥ 90 g/L
- Serum creatinine (Cr) < 1.5 x upper limit of normal(ULN) or creatinine clearance ≥ 50 ml/min.
- Total bilirubin (TBIL) < 1.5 x ULN, AST< 2.5 x ULN, and ALT< 2.5 x ULN
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2, and ability to take oral medication
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 1 year after the end of study intervention administration
- For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner
Exclusion Criteria7
- Received prior anti-AR pathway therapy
- Treatment with another investigational drug or chemotherapy within 6 months
- History of hypothalamus or pituitary dysfunction
- History of seizure
- Clinically uncontrolled diseases, such as septic shock, uncontrolled hypertension, unstable angina, New York Heart Association (NYHA) class III or IV heart disease, clinically unstable arrhythmia, myocardial infarction (in the past 6 months)
- Previous cancer except skin cancer rather than malignant melanoma or any cancer curatively treated > 5 years prior to study entry
- Pregnancy or lactation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Rezvilutamide 240 mg (3\*80mg tablets) will be administered orally once daily with or without food.
The dose and frequency of administration will be consistent with the prescribing information in prostate cancer patients.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06348264